Literature DB >> 21354230

Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study.

Thomas Sersté1, Claire Francoz, François Durand, Pierre-Emmanuel Rautou, Christian Melot, Dominique Valla, Richard Moreau, Didier Lebrec.   

Abstract

BACKGROUND & AIMS: In patients with cirrhosis and refractory ascites the role of beta-blockers in the development of paracentesis-induced circulatory dysfunction (PICD) is unknown. The aim of this study was to investigate the incidence of PICD before and after discontinuation of beta-blockers in patients with cirrhosis and refractory ascites. A self control cross-over study was performed.
METHODS: Patients with cirrhosis and refractory ascites treated with beta-blockers were selected. Heart rate, arterial pressure, and plasma renin concentrations (PRC) were collected before, immediately after and 1 week after large-volume paracentesis associated with intravenous albumin administration. Beta-blocker therapy was progressively discontinued after complete endoscopic eradication of varices. The clinical and biological evaluation was then repeated. The presence of PICD was defined as an increase in PRC of at least 50% above baseline 1 week after paracentesis.
RESULTS: Ten patients were included (nine men, mean age 59.1 ± 10.7 years old). The MELD score was 17.7 ± 4.4 and eight patients were Child-Pugh C. When patients were given beta-blockers, the heart rate did not change immediately after paracentesis while mean arterial pressure significantly decreased; PICD developed in eight patients. After beta-blockers were discontinued, the heart rate significantly increased immediately after paracentesis and mean arterial pressure significantly decreased; PICD only developed in one patient; the difference in the incidence of PICD was significant when these same patients were treated with beta-blockers.
CONCLUSIONS: The use of beta-blockers may be associated with a high risk of PICD in patients with cirrhosis and refractory ascites.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21354230     DOI: 10.1016/j.jhep.2011.01.034

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  40 in total

1.  Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance.

Authors:  Johanne Brooks; Richard Warburton; Ian L P Beales
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

Review 2.  [Renal insufficiency in patients with hepatic insufficiency].

Authors:  K Lenz; M Binder; R Buder; A Gruber; B Gutschreiter; M Voglmayr
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-26       Impact factor: 0.840

Review 3.  Nonselective beta-blockers in cirrhotic patients with no or small varices: A meta-analysis.

Authors:  Xing-Shun Qi; Yong-Xin Bao; Ming Bai; Wen-Da Xu; Jun-Na Dai; Xiao-Zhong Guo
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

4.  Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window.

Authors:  Vincenzo La Mura; Giulia Tosetti; Massimo Primignani; Francesco Salerno
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

5.  I. Beta-blockers: Finding the Right Timing and its Role in Cirrhosis.

Authors:  Ajay K Duseja
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

6.  Beneficial and harmful effects of nonselective beta blockade on acute kidney injury in liver transplant candidates.

Authors:  Sang Gyune Kim; Joseph J Larson; Ji Sung Lee; Terry M Therneau; W Ray Kim
Journal:  Liver Transpl       Date:  2017-06       Impact factor: 5.799

Review 7.  Paracentesis-induced circulatory dysfunction: a primer for the interventional radiologist.

Authors:  Aaron J Lindsay; James Burton; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

8.  Nonselective β-blockers may induce development of portal vein thrombosis in cirrhosis.

Authors:  Xing-Shun Qi; Ming Bai; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 9.  Pharmacologic prevention of variceal bleeding and rebleeding.

Authors:  Anna Baiges; Virginia Hernández-Gea; Jaime Bosch
Journal:  Hepatol Int       Date:  2017-12-05       Impact factor: 6.047

Review 10.  Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites.

Authors:  Antonio Facciorusso; Sunil Roy; Sarantis Livadas; Adwalia Fevrier-Paul; Clara Wekesa; Ismail Dogu Kilic; Amit Kumar Chaurasia; Mina Sadeq; Nicola Muscatiello
Journal:  Dig Dis Sci       Date:  2018-05-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.